Company Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:18:43 2024-04-29 am EDT			5-day change	1st Jan Change
5.335 ^USD	-3.00%		-6.40%	+25.09%

Apr. 24	Transcript : Lantern Pharma Inc. - Special Call
Apr. 22	Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion	MT

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Number of employees: 21

Managers	Title	Age	Since
Panna Sharma CEO	Chief Executive Officer	53	18-06-30
David Margrave DFI	Director of Finance/CFO	64	18-05-31
Reggie Ewesuedo CTO	Chief Tech/Sci/R&D Officer	-	23-03-01
Kishor Bhatia CTO	Chief Tech/Sci/R&D Officer	69	19-11-30
Ernest Kitt CTO	Chief Tech/Sci/R&D Officer	-	23-03-01

Members of the board	Title	Age	Since
Panna Sharma CEO	Chief Executive Officer	53	18-06-30
Maria-Luisa Maccecchini BRD	Director/Board Member	73	22-06-07
Donald Keyser CHM	Chairman	71	17-12-31
Vijay Chandru BRD	Director/Board Member	70	19-09-30
David Silberstein BRD	Director/Board Member	73	18-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,741,324	9,123,744 ( 84.94 %)	0	84.94 %

Name	Equities	%	Valuation
BIOS Capital Management LP 11.77 %	1,263,802	11.77 %	11 M $
Biological Mimetics, Inc. 8.793 %	944,458	8.793 %	8 M $
PROPHASE LABS, INC. 5.876 %	631,195	5.876 %	6 M $
Vanguard Global Advisers LLC 3.401 %	365,334	3.401 %	3 M $
NewEdge Advisors LLC 1.545 %	165,972	1.545 %	1 M $
Geode Capital Management LLC 0.8848 %	95,036	0.8848 %	836 317 $
CM Management LLC 0.7448 %	80,000	0.7448 %	704 000 $
Carlson Capital LP 0.5586 %	60,000	0.5586 %	528 000 $
Commonwealth Equity Services LLC 0.5479 %	58,848	0.5479 %	517 862 $
Renaissance Technologies LLC 0.4078 %	43,800	0.4078 %	385 440 $

Lantern Pharma, Inc.

1920 McKinney Avenue 7th floor

75201, Dallas

http://www.lanternpharma.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.5 USD

Average target price

22 USD

Spread / Average Target

+300.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
LANTERN PHARMA INC.	+25.09%	59.08M
IQVIA HOLDINGS INC.	+2.20%	42.75B
LONZA GROUP AG	+47.81%	41.61B
MODERNA, INC.	+12.46%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.71%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.55%	18.12B
MEDPACE HOLDINGS, INC.	+30.90%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.47%	11B

Other Biotechnology & Medical Research